U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07463599) titled 'Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma' on Feb. 25.
Brief Summary: This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
Study Start Date: Feb. 17
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Carcinoma (mCRC)
Colorectal Cancer (CRC)
Adenomatous Polyposis Coli (APC) Gene Mutation
Catenin Beta-1 (CTNNB1) Gene Mutation
Intervention:
DRUG: Tegavivint
Tegavivint is a first-in-class chemical inhibitor that interfere...